Table 1: Dyslipidemia: Fredrickson Classification System
Table 2: Risk Factors and Comorbidities for Dyslipidemia
Table 3: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia
Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH
Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C
Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG
Table 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C
Table 8: 8MM, Total Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, Selected Years 2015–2025
Table 9: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, Selected Years 2015–2025
Table 10: 8MM, Total Prevalent Cases of Increased LDL-C, Ages =20 Years, Both Sexes, N, Selected Years, 2015–2025
Table 11: 8MM, Total Prevalent Cases of High TG, Ages =20 Years, Both Sexes, N, Selected Years, 2015–2025
Table 12: 8MM, Total Prevalent Cases of Very High TG, Ages =20 Years, Both Sexes, N, Selected Years, 2015–2025
Table 13: 8MM, Total Prevalent Cases of Low HDL-C, Ages =20 Years, Both Sexes, N, Selected Years 2015–2025
Table 14: AACE Optimal/Near-Optimal, Borderline, and High-Risk Serum Lipid Concentrations
Table 15: Factors Considered for Different CVD Risk Calculators
Table 16: Treatment Guidelines for Dyslipidemia
Table 17: Most Prescribed Drugs for Dyslipidemia by Class in the Global Markets, 2015
Table 18: Country Profile – US
Table 19: Market Profile – 5EU
Table 20: Country Profile – Japan
Table 21: Intensity level of commonly used statins
Table 22: Product Profile – Crestor (Rosuvastatin)
Table 23: Efficacy of Rosuvastatin – Lipid and Lipoprotein Parameters
Table 24: Crestor SWOT Analysis, 2015
Table 25: Product Profile – Zetia
Table 26: Efficacy of Zetia – Primary and Secondary Endpoints, IMPROVE-IT study
Table 27: Safety of Zetia (Ezetimibe)
Table 28: Drug Zetia (Ezetimibe) SWOT Analysis, 2015–2025
Table 29: Product Profile – Praluent
Table 30: Efficacy of Praluent (alirocumab) – Primary and Secondary Endpoints, ODYSSEY LONG TERM Phase III Study
Table 31: Safety of Praluent (alirocumab)
Table 32: Praluent (Alirocumab) SWOT Analysis, 2015–2025
Table 33: Product Profile – Repatha
Table 34: Pivotal Trials of Repatha (Evolocumab)
Table 35: Repatha (Evolocumab) SWOT Analysis, 2015-2025
Table 36: Product Profile – Vytorin
Table 37: Efficacy of Vytorin – Primary and Secondary Endpoints, VYVA study
Table 38: Vytorin SWOT Analysis, 2015
Table 39: Product Profile – Kynamro
Table 40: Efficacy of Kynamro – Lipid and Lipoprotein Parameters, RADICHOL 1 Phase III Study
Table 41: Safety of Kynamro (mipomersen)
Table 42: Kynamro SWOT Analysis, 2015
Table 43: Product Profile – Juxtapid
Table 44: Efficacy of Juxtapid – Lipid and Lipoprotein parameters, Phase III Study
Table 45: Juxtapid SWOT Analysis, 2015
Table 46: Product Profile – Niaspan
Table 47: Niacin/Nicotinic Acid SWOT Analysis, 2015
Table 48: Summary of the Therapeutic Properties of Fibrates*
Table 49: Product Profile – Tricor/Trilipix
Table 50: Tricor/Trilipix SWOT Analysis, 2015
Table 51: Product Profile – Lovaza
Table 52: Efficacy of Lovaza – Pivotal Studies for the Treatment of Very High TGs
Table 53: Lovaza SWOT Analysis, 2015
Table 54: Product Profile – Vascepa
Table 55: Efficacy of Vascepa – ANCHOR Phase III Study
Table 56: Vascepa SWOT Analysis, 2015
Table 57: Product Profile – Epanova
Table 58: Efficacy of Epanova – ESPRIT Phase III Study
Table 59: Epanova SWOT Analysis, 2015
Table 60: Product Profile – Welchol
Table 61: Efficacy of Welchol – GLOWS Study
Table 62: Welchol SWOT Analysis, 2015
Table 63: Unmet Need and Opportunity in Dyslipidemia, 2015
Table 64: Product Profile – LY3015014
Table 65: Efficacy of LY3015014
Table 66: LY3015014 SWOT Analysis, 2015
Table 67: Product Profile – Anacetrapib
Table 68: Efficacy of Anacetrapib – Primary and Secondary Endpoints, DEFINE study
Table 69: Safety of Anacetrapib – AEs and Safety Variables, DEFINE study
Table 70: Anacetrapib SWOT Analysis, 2015
Table 71: Product Profile – AMG-899 ( TA-8995/DEZ-001)
Table 72: Efficacy of TA-8995 – Primary Endpoints, TULIP study
Table 73: AMG-899 SWOT Analysis, 2015
Table 74: Product Profile – ETC-1002 (Bempedoic Acid)
Table 75: Efficacy of ETC-1002 – Lipid and lipoprotein parameters
Table 76: ETC-1002 SWOT Analysis, 2015
Table 77: Product Profile – Volanesorsen
Table 78: Efficacy of Volanesorsen – Lipid and Lipoprotein Levels and Glycemic Control
Table 79: Volanesorsen SWOT Analysis, 2015
Table 80: Product Profile – CER-001
Table 81: Efficacy of CER-001
Table 82: CER-001 SWOT Analysis, 2015
Table 83: Product Profile – ALN-PCSsc
Table 84: ALN-PCSsc SWOT Analysis, 2015
Table 85: Product Profile – Gemcabene
Table 86: Efficacy of Gemcabene
Table 87: Gemcabene SWOT Analysis, 2015
Table 88: Product Profile – Pemafibrate
Table 89: Efficacy of Pemafibrate
Table 90: Safety of Pemafibrate
Table 91: Pemafibrate SWOT Analysis, 2015
Table 92: Drugs in Development for Dyslipidemia, 2015
Table 93: Key Companies in the Dyslipidemia Market in the 7MM, 2015
Table 94: Abbvie’s Dyslipidemia Portfolio Assessment, 2015
Table 95: Aegerion Pharmaceuticals’ Dyslipidemia Portfolio Assessment, 2015
Table 96: Ionis Pharmaceuticals’ Dyslipidemia Portfolio Assessment, 2015
Table 97: Amarin’s Dyslipidemia Portfolio Assessment, 2015
Table 98: Amgen’s Dyslipidemia Portfolio Assessment, 2015
Table 99: AstraZeneca’s Dyslipidemia Portfolio Assessment, 2015
Table 100: Cerenis Therapeutics’ Dyslipidemia Portfolio Assessment, 2015
Table 101: Daiichi Sankyo’s Dyslipidemia Portfolio Assessment, 2015
Table 102: Eli Lilly’s Dyslipidemia Portfolio Assessment, 2015
Table 103: Esperion Therapeutics’ Dyslipidemia Portfolio Assessment, 2015
Table 104: Genzyme’s Dyslipidemia Portfolio Assessment, 2015
Table 105: Merck & Co.’s Dyslipidemia Portfolio Assessment, 2015
Table 106: Regeneron Pharmaceuticals’ Dyslipidemia Portfolio Assessment, 2015
Table 107: Sanofi’s Dyslipidemia Portfolio Assessment, 2015
Table 108: The Medicines Company’s Dyslipidemia Portfolio Assessment, 2015
Table 109: Dyslipidemia Market – Global Drivers and Barriers, 2015?2025
Table 110: Key Events Impacting Sales for Dyslipidemia in the US, 2015–2025
Table 111: Dyslipidemia Market – Drivers and Barriers in the US, 2015?2025
Table 112: Key Events Impacting Sales for Dyslipidemia in the 5EU, 2015–2025
Table 113: Dyslipidemia Market – Drivers and Barriers in the 5EU, 2015?2025
Table 114: National Healthcare Authorities in the 5EU Nations
Table 115: National Public Health Initiatives in the 5EU Nations
Table 116: Governmental Drug Pricing Authorities in the 5EU Nations
Table 117: Key Events Impacting Sales for Dyslipidemia in Japan, 2015–2025
Table 118: Dyslipidemia Market – Drivers and Barriers in Japan, 2015?2025
Table 119: Key Launch Dates for Dyslipidemia
Table 120: Key Patent Expiry Dates for Dyslipidemia
Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
